Primary chemotherapy for early breast cancer

Cancer Treatment Reviews

Volumn 22, Issue 6, 1996, Pages 437-450

  Ellis, P A ^a   Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; THIOTEPA; VINCRISTINE; VINDESINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FEMALE; HUMAN;

EID: 0030438685     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90025-0     Document Type: Article

References (47)

1. Fisher, B. (1992) The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res. 52: 2371-2383.
2. Fisher, B., Anderson, S. & Redmond, C. (1995) Reanalysis and results after 12 years of followup in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New Engl. J. Med. 333: 1456-1461.
3. EBCTG (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85.
4. Hortobagyi, G. N., Ames, F. C. & Buzdar, A. U. (1988) Management of stage 3 primary breast cancer with primary chemotherapy, surgery, radiation therapy. Cancer 62: 2507-2516.
5. Jones, A. L., Smith, I. E., O'Brien, M. E. R. (1994) Phase 2 study of continuous infusional 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastic and locally advanced breast cancer: an active new regimen. J. Clin. Oncol. 12: 1259-1265.
6. Swain, S. M., Sorace, R. A. & Bagley, C. S. (1987) Neo-adjuvant chemotherapy in the combined modality approach of locally advanced breast cancer. Cancer Res. 47: 3889-3894.
7. Haagensen, C. D. & Stout, A. P. (1943) Carcinoma of the breast: Criteria of inoperability. Ann. Surg. 118: 1259-1265.
8. Simpson-Herren, L., Sanford, A. H. & Holmquist, J. P. (1976) Effects of surgery on the cell kinetics of residual tumour. Cancer Treat. Rep. 60: 1749-1760.
9. Ketcham, A. S., Wexler, H. & Mantel, N. (1961) The development of spontaneous metastases after the removal of the primary tumour. Cancer 14: 875-882.
10. Gunduz, N., Fisher, B. & Saffer, E. A. (1979) Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res. 39: 3861-3865.
11. Fisher, B., Gunduz, N. & Saffer, F. A. (1983) Influence of the interval between primary tumour removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 43: 1488-1492.
12. Fisher, B., Gunduz, N., Coyle, Rudock, C. & Saffer, E.: (1989) Presence of a growth stimulating factor in serum following primary tumour removal in mice. Cancer Res. 49: 1996-2001.
13. Fisher, B., Saffer, E. A. & Rudock, C. (1989) Effect of local or systemic treatment prior to primary tumour removal on the production of, and response to, a serum stimulating factor in mice. Cancer Res. 49: 2002-2004.
14. Holmgren, L., O'Reilly, M. S. & Folkman, J. (1995) Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1: 149-153.
15. Jacquillat, C., Weil, M., Baillet, F. et al. (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129.
16. Forrest, A. P., Levack, P. A., Chetty, U. et al. (1986) A human tumour model. Lancet 2: 840-842.
17. Anderson, E. D., Forrest, A. P., Hawkins, R. A., Anderson, T. J., Leonard, R. C. F. & Chetty, U. (1991) Primary systemic therapy for operable breast cancer. Brit. J. Cancer 63: 561-566.
18. Smith, I. E., Jones, A. L, O'Brien, M. E. R., MacKinna, A., Sacks, N. & Baum, M. (1993) Primary medical (neoadjuvant) chemotherapy for operable breast cancer, Eur. J. Cancer 29A: 1796-1799.
19. Smith, I. E., Walsh, G., Jones, A. L. et al. (1995): High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J. Clin. Oncol. 12: 1259-1265.
20. Bonadonna, G., Valagussa, P., Zucali, R. & Salvadori, B. (1995) Primary chemotherapy in surgically resectable breast cancer. Ca. Cancer J. Clin, 45: 227-243.
21. Bernardo, G., Plastina, M., Bernardo, G., Strada, M. R., Bottero, G. & Betta, P. G.: (1995) Neoadjuvant chemotherapy (cyclophosphamide, epirubicin and fluoracil) plus G-CSF for operable breast cancer. Proc. Am. Soc. Clin. Oncol. 14: A201.
22. Chollet, P., Charrier, S., Brain, E. et al. (1995) High pathological response rate induced by intensive anthracycline-based regimen. Proc. Am. Soc. Clin. Oncol. 14: A218.
23. Mauriac, L., Durand, M., Avril, A. & Dilhuydy, J. M. (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3cm. Results of a randomized trial in a single centre. Ann. Oncol. 2: 347-354.
24. Scholl, S. M., Fourquet, A., Asselain, B. et al. (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur. J. Cancer 30A: 645-652.
25. Scholl, S. M.,Asselain, B., Beuzeboc, P. et al. (1995) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. Proc. Am. Soc. Clin. Oncol. 14: A200.
26. Semiglazov, V. F., Topuzov, E. E., Bavli, J. L. et al. (1994) Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann. Oncol. 5: 591-595.
27. Danforth, D., Jacobson, J., O'Shaughnessy, J. et al. (1995) Effect of pre-operative chemotherapy on axillary lymph node metastases in stage II breast cancer. Proc. Am. Soc. Clin. Oncol. 14: A213.
28. Powles, T. J., Hickish, T. F., Makris, A. et al. (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J. Clin. Oncol. 13: 547-552.
29. Makris, A., Powles, T. J., Ashley, S. E., Dowsett, M., Allred, D. C. & Trott, P. (1996) A randomised trial of neoadjuvant chemo-endocrine therapy in operable breast cancer. Proc. Am. Soc. Clin. Oncol. 15: A51.
30. Fisher, B., Rockette, H., Robidoux, A. et al. (1994) Effect of pre-operative therapy for breast cancer on local-regional disease: First report of NSABP B-18. Proc. Am. Soc. Clin. Oncol. 13: A57.
31. Calais, G., Berger, C., Descamps, P. et al. (1994) Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74: 1283-1288.
32. Scholl, S. M., Pierga, J. Y, Asselain, B. et al. (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur. J. Cancer 31A: 1969-1975.
33. Botti, C., Vici, P., Lopez, M., Scinto, A. F., Cognetti, F. & Cavaliere, R. (1995) Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J. Am. Coll. Surg. 181: 202-208.
34. Ferriere, J. P., Assier, I., Cure, H. et al. (1996) Primary chemotherapy in breast cancer: Correlation between tumour response and patient outcome. Proc. Am. Soc. Clin, Oncol. 15: A84.
35. MacGrogan, G., Mauriac, L., Durand, M. et al. (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB2, Mib-1, pS2, and GSTpi. Brit. J. Cancer 74: 1458-1465.
36. Daidone, M. G., Silvestrini, R., Luisi, A. et al. (1995) Changes in biological markers after primary chemotherapy for breast cancers. Int. J. Cancer 61: 301-305.
37. Ellis, P. A., Detre, S., Burton, S. A., Salter, J. & Dowsett, M. (1966) Changes in proliferation, apoptosis, and Bcl-2 expression in breast cancer specimens after neoadjuvant chemotherapy. Breast Can. Res. Treat. 37: 3.
38. Collecchi, P., Giannessi, P. G., Baldini, E. et al. (1996) Effects of primary chemotherapy on biological parameters of locally advanced breast cancer. Ann. New York Acad. Sci. 784: 419-426.
39. Chevillard, S., Pouillart, P., Beldjord, P. et al. (1996) Sequential assessment of multi-drug resistance phenotype and measurement of s-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300.
40. O'Reilly, S. M., Camplejohn, R. S., Rubens, R. D. & Richards, M. A. (1992) DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur. J. Cancer 28: 681-683.
41. Ellis, P. A., Smith, I. E., Salter, J., O'Brien, M. E. R., Ramage, F. & Dowsett, M. (1996) Preoperative chemotherapy for early breast cancer induces apoptosis. Proc. Am. Soc. Clin. Oncol. 15: A112.
42. Hammond, S., Keyhani-Rofagha, S. & O'Toole, R. V. (1987) Statistical analysis of fine needle aspiration cytology of the breast: A review of 678 cases plus 4265 cases from the literature. Acta. Cytol. 31: 276-280.
43. Seymour, M. T., Moskovic, E. C., Walsh, G. & Smith, I. E. (1996) Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer. Brit. J. Cancer (In press).
44. Gianni, L., Munzone, E., Capri, G. et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 13: 2688-2699.
45. Chollet, P., Belambaogo, E. & Baillet, F. (1993) Four year results of neoadjuvant chemotherapy for 148 operable breast cancers. Proc. Am. Soc. Clin. Oncol. 12: A157.
46. Lara, F. U., Zinser, J. W., Cataneda, N., Ramirez, M. T., Maafs, E. & Perez, V. M. (1995) Neoadjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) in stage II-III breast cancer. Proc. Am. Soc. Clin. Oncol. 14: A179.
47. Van Praagh, I., Leduc, B., Cure, H. et al. (1995) Neoadjuvant VEM chemotherapy regimen for operable breast cancer: results of a co-operative study on 69 patients. Proc. Am. Soc. Clin. Oncol. 14: A242.